US Cuts Could Jeopardize Global Health Innovations, Says Report

February 19, 2013
Julian Upton

Julian Upton is Pharmaceutical Executive's Online and European Editor. He can be reached at jupton@mjhlifesciences.com

Pharmaceutical Executive

Cuts to US global health and research programs for diseases such as AIDS, tuberculosis and malaria risk derailing the innovations crucial to fighting these diseases, according a new report by the Global Health Technologies Coalition.

Cuts to US global health and research programs for diseases such as AIDS, tuberculosis and malaria risk derailing the innovations crucial to fighting these diseases, according a new report by the Global Health Technologies Coalition.

The report asserts that without continued and consistent US investment in global health research - which has so far “helped deliver some of the greatest advances the field has ever seen” - the momentum needed to do drive these advances “over the finish line” will be compromised.

The report will be released at a congressional briefing at noon, Tuesday, February 26,  at the Russell Senate Office Building, Washington, DC. An expert panel - including Dr Caroline Ryan, Director of Technical Leadership, Office of the Global AIDS Coordinator, Department of State, PEPFAR (President’s Emergency Plan for AIDS Relief) and Dr Alan Magill, Director of Malaria, Bill & Melinda Gates Foundation - will be speaking at the event.

For more information, contact Katy Lenard (klenard@burnesscommunications.com)
T: +1 301-280-5719

Related Content:

News